These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 7377225)

  • 1. Reversible melphalan-induced lung damage.
    Westerfield BT; Michalski JP; McCombs C; Light RW
    Am J Med; 1980 May; 68(5):767-71. PubMed ID: 7377225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulmonary histopathologic changes associated with melphalan therapy.
    Taetle R; Dickman PS; Feldman PS
    Cancer; 1978 Sep; 42(3):1239-45. PubMed ID: 359122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulmonary fibrosis following therapy with Melphalan for multiple myeloma.
    Codling BW; Chakera TM
    J Clin Pathol; 1972 Aug; 25(8):668-73. PubMed ID: 5076801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Acute, reversible, interstitial pneumopathy induced by melphalan].
    Lioté H; Gauthier JF; Prier A; Gauthier-Rahman S; Kaplan G; Akoun G
    Rev Mal Respir; 1989; 6(5):461-4. PubMed ID: 2690210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Interstitial pneumopathy caused by melphalan].
    Lustman F; Salhadin A; Dufrane JP
    Rev Mal Respir; 1986; 3(2):115-7. PubMed ID: 3726261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melphalan-induced pulmonary interstitial fibrosis.
    Goucher G; Rowland V; Hawkins J
    Chest; 1980 Jun; 77(6):805-6. PubMed ID: 7398396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melphalan-associated pulmonary toxicity following high-dose therapy with autologous hematopoietic stem cell transplantation.
    Akasheh MS; Freytes CO; Vesole DH
    Bone Marrow Transplant; 2000 Nov; 26(10):1107-9. PubMed ID: 11108311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lung toxicity associated with cyclophosphamide use. Two distinct patterns.
    Malik SW; Myers JL; DeRemee RA; Specks U
    Am J Respir Crit Care Med; 1996 Dec; 154(6 Pt 1):1851-6. PubMed ID: 8970380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group.
    Ann Intern Med; 1996 Jan; 124(2):212-22. PubMed ID: 8533996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A rare case of interstitial pneumonitis after tandem high-dose melphalan conditioning and autologous stem cell transplantation in multiple myeloma.
    Buxhofer-Ausch V; Ruckser R; Kier P; Habertheuer KH; Zelenka P; Tatzreiter G; Ausch C; Schmid I; Hruby W; Reiner-Concin A; Sebesta C; Ogris E; Hinterberger-Fischer M; Hinterberger W
    Eur J Haematol; 2004 Aug; 73(2):143-6. PubMed ID: 15245515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversible interstitial pneumonitis associated with low dose bleomycin.
    O'Neill TJ; Kardinal CG; Tierney LM
    Chest; 1975 Aug; 68(2):265-7. PubMed ID: 50163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible pulmonary toxicity secondary to vinblastine.
    Konits PH; Aisner J; Sutherland JC; Wiernik PH
    Cancer; 1982 Dec; 50(12):2771-4. PubMed ID: 7139567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melphalan-induced pulmonary fibrosis in osteosclerotic myeloma.
    Mufti GJ; Hamblin TJ; Gordon J
    Acta Haematol; 1983; 69(2):140-1. PubMed ID: 6404091
    [No Abstract]   [Full Text] [Related]  

  • 14. Cytomegalovirus pneumonia after treatment with melphalan and prednisone. Report of a case.
    von Eyben F; Olsen TS
    Acta Med Scand; 1978; 203(4):333-5. PubMed ID: 206105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
    Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
    J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary fibrosis following therapy with melphalan: report of two cases.
    Major PP; Laurin S; Bettez P
    Can Med Assoc J; 1980 Aug; 123(3):197-202. PubMed ID: 7260761
    [No Abstract]   [Full Text] [Related]  

  • 17. Enhanced alveolar macrophage-mediated antigen-induced T-lymphocyte proliferation in sarcoidosis.
    Venet A; Hance AJ; Saltini C; Robinson BW; Crystal RG
    J Clin Invest; 1985 Jan; 75(1):293-301. PubMed ID: 3871200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity in standard melphalan-prednisone therapy among myeloma patients with renal failure--a retrospective analysis and recommendations for dose adjustment.
    Carlson K; Hjorth M; Knudsen LM;
    Br J Haematol; 2005 Mar; 128(5):631-5. PubMed ID: 15725084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preferential in vivo DNA repair of melphalan-induced damage in human genes is greatly affected by the local chromatin structure.
    Souliotis VL; Dimopoulos MA; Episkopou HG; Kyrtopoulos SA; Sfikakis PP
    DNA Repair (Amst); 2006 Aug; 5(8):972-85. PubMed ID: 16781199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Additive pulmonary toxicity with melphalan and busulfan therapy.
    Schallier D; Impens N; Warson F; Van Belle S; De Wasch G
    Chest; 1983 Oct; 84(4):492-3. PubMed ID: 6578007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.